Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Hold" by Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has been assigned a consensus rating of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $15.17.

ELAN has been the subject of a number of research reports. UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Piper Sandler decreased their price objective on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Stifel Nicolaus cut their target price on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a report on Friday, February 21st. Finally, Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price target on the stock.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the acquisition, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.57% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. raised its holdings in shares of Elanco Animal Health by 10.2% during the third quarter. Victory Capital Management Inc. now owns 102,414 shares of the company's stock valued at $1,504,000 after purchasing an additional 9,480 shares during the period. Quest Partners LLC raised its stake in Elanco Animal Health by 915.1% during the 3rd quarter. Quest Partners LLC now owns 16,201 shares of the company's stock worth $238,000 after buying an additional 14,605 shares during the period. Commerce Bank boosted its holdings in Elanco Animal Health by 2.2% in the third quarter. Commerce Bank now owns 35,114 shares of the company's stock worth $516,000 after acquiring an additional 741 shares in the last quarter. Bank of Montreal Can grew its stake in Elanco Animal Health by 3.5% in the third quarter. Bank of Montreal Can now owns 416,336 shares of the company's stock valued at $5,962,000 after acquiring an additional 14,190 shares during the period. Finally, Qsemble Capital Management LP bought a new stake in shares of Elanco Animal Health during the third quarter valued at approximately $264,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Price Performance

Shares of ELAN stock traded down $0.42 on Wednesday, reaching $10.40. The company had a trading volume of 4,189,495 shares, compared to its average volume of 4,788,321. The business's 50-day moving average is $11.23 and its 200 day moving average is $12.44. The stock has a market capitalization of $5.14 billion, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. Elanco Animal Health has a one year low of $10.03 and a one year high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm posted $0.08 EPS. The business's quarterly revenue was down 1.4% compared to the same quarter last year. Equities research analysts forecast that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.